给新西兰白兔注射[14C]达巴万星后，放射性在骨骼及相关结构中的分布情况。
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
作者信息
Solon Eric G, Dowell James A, Lee Jonghui, King S Peter, Damle Bharat D
机构信息
Quest Pharmaceuticals Services, Newark, DE, USA.
出版信息
Antimicrob Agents Chemother. 2007 Aug;51(8):3008-10. doi: 10.1128/AAC.00020-07. Epub 2007 Jun 4.
Abstract
Penetration of dalbavancin into noninfected bone and joint tissues was assessed after an intravenous dose of 20 mg/kg (of body weight) [(14)C]dalbavancin given to rabbits. Drug-derived radioactivity, determined over 14 days by either liquid scintillation counting or autoradiography, remained above the MIC for common gram-positive pathogens that cause bone and joint infections.
摘要
在给兔子静脉注射20mg/kg（体重）的[¹⁴C]达巴万星后，评估了达巴万星在未感染的骨和关节组织中的渗透情况。通过液体闪烁计数或放射自显影在14天内测定的药物衍生放射性，对于引起骨和关节感染的常见革兰氏阳性病原体而言，仍高于最低抑菌浓度。
相似文献
1
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
Antimicrob Agents Chemother. 2007 Aug;51(8):3008-10. doi: 10.1128/AAC.00020-07. Epub 2007 Jun 4.
2
Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02089-19.
3
Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.
4
Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
Expert Opin Investig Drugs. 2007 May;16(5):717-33. doi: 10.1517/13543784.16.5.717.
5
Dalbavancin: a new option for the treatment of gram-positive infections.
Ann Pharmacother. 2006 Mar;40(3):449-60. doi: 10.1345/aph.1G158. Epub 2006 Feb 28.
6
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Diagn Microbiol Infect Dis. 2005 Dec;53(4):307-10. doi: 10.1016/j.diagmicrobio.2005.03.004.
7
Effect of dalbavancin on the normal intestinal microflora.
J Antimicrob Chemother. 2006 Sep;58(3):627-31. doi: 10.1093/jac/dkl281. Epub 2006 Jul 12.
8
Dalbavancin: a new lipoglycopeptide antibiotic.
Am J Health Syst Pharm. 2008 Apr 1;65(7):599-610. doi: 10.2146/ajhp070255.
9
Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Drugs. 2017 Jan;77(1):75-83. doi: 10.1007/s40265-016-0666-0.
10
Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.
Antimicrob Agents Chemother. 1998 Nov;42(11):2830-5. doi: 10.1128/AAC.42.11.2830.
引用本文的文献
1
Orthopaedic Implant-Associated Staphylococcal Infections: A Critical Reappraisal of Unmet Clinical Needs Associated with the Implementation of the Best Antibiotic Choice.
Antibiotics (Basel). 2022 Mar 17;11(3):406. doi: 10.3390/antibiotics11030406.
2
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
Clin Pharmacokinet. 2022 Mar;61(3):363-374. doi: 10.1007/s40262-021-01088-w. Epub 2021 Dec 21.
3
Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
Biomedicines. 2021 Sep 22;9(10):1288. doi: 10.3390/biomedicines9101288.
4
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.
Antibiotics (Basel). 2021 May 31;10(6):656. doi: 10.3390/antibiotics10060656.
5
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization.
Ther Clin Risk Manag. 2021 Mar 22;17:223-232. doi: 10.2147/TCRM.S271445. eCollection 2021.
6
Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study.
Saudi Pharm J. 2020 Apr;28(4):460-464. doi: 10.1016/j.jsps.2020.02.007. Epub 2020 Feb 17.
7
A young patient with fever after heart transplantation.
Rev Esp Quimioter. 2018 Oct;31(5):452-454. Epub 2018 Sep 14.
8
Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Am J Case Rep. 2017 Dec 9;18:1315-1319. doi: 10.12659/ajcr.905930.
9
Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01784-16. Print 2017 Jan.
10
Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.
Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5. doi: 10.1128/AAC.00981-15. Epub 2015 Aug 3.
本文引用的文献
1
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Diagn Microbiol Infect Dis. 2006 Feb;54(2):149-53. doi: 10.1016/j.diagmicrobio.2005.08.015. Epub 2006 Jan 19.
2
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.
J Clin Pharmacol. 2005 Nov;45(11):1279-87. doi: 10.1177/0091270005280378.
3
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Clin Infect Dis. 2005 Nov 15;41(10):1407-15. doi: 10.1086/497271. Epub 2005 Oct 6.
4
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii25-30. doi: 10.1093/jac/dki008.
5
Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Antimicrob Agents Chemother. 2005 Feb;49(2):770-2. doi: 10.1128/AAC.49.2.770-772.2005.
6
Antibiotic treatment of gram-positive bone and joint infections.
J Antimicrob Chemother. 2004 Jun;53(6):928-35. doi: 10.1093/jac/dkh191. Epub 2004 Apr 29.
7
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Diagn Microbiol Infect Dis. 2004 Feb;48(2):137-43. doi: 10.1016/j.diagmicrobio.2003.09.004.
8
Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clin Infect Dis. 2001 May 15;32 Suppl 2:S114-32. doi: 10.1086/320184.
9
Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.
Antimicrob Agents Chemother. 1998 Nov;42(11):2830-5. doi: 10.1128/AAC.42.11.2830.
Zotero 插件